Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $5.00

Gossamer Bio, Inc. (NASDAQ:GOSS) has been given an average recommendation of “Hold” by the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $5.00.

Several equities analysts have recently commented on GOSS shares. Wedbush reaffirmed a “neutral” rating and issued a $1.00 target price (down from $6.00) on shares of Gossamer Bio in a research report on Tuesday, February 24th. Royal Bank Of Canada raised Gossamer Bio to an “outperform” rating in a report on Tuesday, February 24th. Weiss Ratings lowered Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. The Goldman Sachs Group cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Leerink Partners downgraded Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $0.17 on Friday. Gossamer Bio has a 52 week low of $0.14 and a 52 week high of $3.87. The company has a market capitalization of $39.43 million, a price-to-earnings ratio of -0.21 and a beta of 2.00. The company has a 50-day simple moving average of $0.28 and a 200 day simple moving average of $1.39.

Gossamer Bio (NASDAQ:GOSS) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $16.96 million for the quarter, compared to analysts’ expectations of $4.67 million. Sell-side analysts forecast that Gossamer Bio will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Gossamer Bio

A number of hedge funds have recently bought and sold shares of GOSS. Vanguard Group Inc. boosted its holdings in Gossamer Bio by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,009,773 shares of the company’s stock valued at $31,586,000 after purchasing an additional 598,981 shares during the period. Kalehua Capital Management LLC acquired a new position in shares of Gossamer Bio during the 1st quarter worth approximately $3,363,000. State Street Corp increased its holdings in shares of Gossamer Bio by 139.7% during the fourth quarter. State Street Corp now owns 9,310,969 shares of the company’s stock worth $28,864,000 after purchasing an additional 5,427,302 shares during the period. Geode Capital Management LLC increased its holdings in shares of Gossamer Bio by 3.9% during the fourth quarter. Geode Capital Management LLC now owns 4,872,714 shares of the company’s stock worth $15,109,000 after purchasing an additional 183,183 shares during the period. Finally, Corient Private Wealth LLC raised its position in shares of Gossamer Bio by 19,123.7% in the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock valued at $11,922,000 after buying an additional 3,825,879 shares in the last quarter. 81.23% of the stock is owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.